Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound Io Therapeutics, Inc presented studies in multiple cancers with its novel drug that inhibits tumor growth by promoting tumor infiltrating T-lymphocytes

CAR-T Therapy Pipeline Landscape Report, 2024 - Features Insights on Emerging Drugs CT053, Descartes-08, ALLO-501A, CTX110, and IMPT 314 Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "CAR-T Therapy - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.This report provides in-depth insights into the...

Tumor Infiltrating Lymphocytes Industry Projected to Reach $18.32 Billion by 2028 - Emerging Technologies, such as cytoDRIVE, and Strategic Alliances Propelling the Global Market Forward Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Tumor Infiltrating Lymphocytes Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Global Growth Driven by...

Global Tumor Infiltrating Lymphocytes TIL Immunotherapy Markers Market Size Research Companies Clinical Trials Outlook Report 2025 DELHI, India, Oct. 22, 2020 (GLOBE NEWSWIRE) -- "Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025" Report Highlights: Tumor Infiltrating...